Pinterest Inc vs TG Therapeutics Inc — how do they compare? Pinterest Inc trades at $18.4 (market cap $11.41B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Pinterest Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals.
| PINS | TGTX | |
|---|---|---|
Market Cap | $11.41B | $8.53B |
Sector | Media | Health |
52-Week High | $36.49 | $59.06 |
52-Week Low | $15.42 | $26.94 |
Enterprise Value | $11.33B | $8.74B |
Signals from Pluang's Aura AI — not financial advice
Pinterest (PINS) trades at $20.14, down 1.27% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth from $2.8B in 2022 to $4.2B in 2025, though net income margin compressed to 5.46%. Recent CFO resignation and insider selling have weighed on sentiment, while analyst consensus remains bullish with a $28.69 price target representing 42% upside potential.
PINS offers significant upside based on analyst targets but faces near-term headwinds from leadership transition and competitive pressures. The stock's high P/E ratio of 59.24 requires continued execution on AI-driven growth initiatives. Key risks include market share competition and the company's ability to monetize international users effectively while managing rising infrastructure costs from the $4B AWS partnership.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Trailing returns across standard periods
Latest headlines on both assets
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →